Rate of Protein Synthesis can Influence Hematopoietic Stem Cells Function
In Part I of this series we introduced T cell based immunotherapy and in Part II we discussed how chimeric antigen receptors (CARs) expressing T cells can be even more potent. In Part III below, we expand this concept further by covering hematopoetic stem cells and additional ways they can be engineered for promising immunotherapy of cancer and leukemia.
In the first part of this series we introduced the concept of cell-based immunotherapy with T cell transplants. Next, we describe an even more potent approach to cancer treatment with T cells that are engineered to express anti-tumor molecules or cell surface tumor-identifying killer receptors. The latter of which are called chimeric antigen receptors, or CARs.
Cell therapy is thought to be the ultimate treatment for degenerative disease and cancer. Stem cells or progenitor cell transplantation will replace those damaged cells or tissue, because stem cells are immature, un-differentiated cells that have potential to produce a variety of cells in our body. The majority of stem cell therapy options (embryonic stem cell, patient specific induced pluripotent stem cells, neural stem cells and mesenchymal stem cells) are still in animal experimental or pre-clinical stage. Currently, only hematopoietic stem cells (HSCs) are used in the clinic to treat patients with cancer, blood or immune defects. High quality hematopoietic stem cells can be purchase from HemaCare.
The immune system undergoes dynamic changes to counteract infection with pathogens or inflammation. This includes the bone marrow, whose diverse cell population is profoundly altered in proportion.